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ABSTRACT
Background:
Leiomyosarcoma (LMS) represents about 1% of primary malignancies of the stomach, 
usually evolves with hepatic implants in 2-thirds of cases, and the outcome is 
frequently poor. With an insidious course, late diagnosis and misdiagnosis with other 
gastric neoplasia occur. Immunohistochemical evaluations are mandatory to confirm 
the diagnostic hypothesis. Surgical resection has been the more effective treatment of 
gastric LMS; however, recurrences after resections and distant metastases may develop 
in up to 50% of the patients. Doxorubicin, gemcitabine, and docetaxel are therapeutic 
options, with variable responses. 
Case presentation:
The 52-year-old male herein described with a diagnosis of LMS in the gastric pouch and 
liver metastasis underwent a Roux-en-Y bypass to treat morbid obesity more than a decade 
ago. Persistent abdominal pain was a unique symptom, and he had liver metastasis at 
diagnosis. The initial hypothesis was a metastatic gastrointestinal stromal tumor (GIST) 
of the excluded stomach and the patient underwent a schedule with imatinib without 
significant response. After a complete revision of the anatomopathological findings, 
the patient underwent a new biopsy of the gastric mass, and the immunohistochemical 
data were consistent with LMS. Then doxorubicin replaced imatinib, later changed 
by gemcitabine associated with docetaxel. As last control found lesions in the central 
nervous system, he is under radiotherapy sessions. 
Conclusion: 
The diagnosis of gastric LMS often occurs at late stages because of the insidious 
clinical course. The rate of liver metastasis at diagnosis is high. Besides, the relatively 
poor response to the alternative management for non-surgical stages of the disease 
yields severe outcomes. 
Keywords:
Leiomyosarcoma, liver metastasis, Roux-en-Y gastric bypass surgery. 
© The Author(s) 2020. Published by ED Marketing & Communication. All rights reserved.
Silva NA, et al./ JGS 2 (2020) 
doi: 10.36159/jgs.v2i3.57
www.journalofgastricsurgery.com99
Background:
Leiomyosarcoma (LMS) represents about 1% of primary 
malignancies of the stomach, evolves with hepatic 
implants in 2-thirds of cases, and the outcome is often 
poor [1-7]. Immunosuppression, Epstein-Barr virus, 
chemicals, and radiation can be related factors [2,6]. 
Spindle cells of the muscularis propria or muscularis 
mucosa present high proliferation rates and positivity 
for desmin, a–muscle-specific actin, and vimentin [2,3,6]. 
Although immunohistochemical findings can avoid 
pitfalls with other gastrointestinal tumors, the diagnosis 
often occurs at late stages because of the insidious clinical 
course [2-7]. LMS predominantly affects female adults 
(5:3) and the sixth decade of life, pain occurs in near 75% 
of patients and the control is very difficult in most of 
them [1,2]. Bleeding, weight loss, and gastroesophageal 
reflux are other frequent symptoms [2-4]. Whenever 
possible, surgical resection is the effective treatment; 
otherwise, palliative care and repeated hepatectomy 
for metastasis resection may prolong the survival rate 
in some cases [1-5]. Recurrences after resections and 
distant metastases may develop in up to 50% of patients 
[5]. Anthracycline-based chemotherapy, ifosfamide, 
gemcitabine, docetaxel, trabectedin, and pazopanib 
constitute additional therapeutic options, with variable 
response rates [6,7]. Because of the exceeding rarity, case 
reports can increase the understanding of gastric LMS. 
Case Report
A 53-year-old Caucasian male who underwent a Roux-
en-Y gastric bypass (RYGB) in 2005 due to grade III 
obesity, and laparoscopic cholecystectomy in 2006, was 
admitted in 2018 claiming of abdominal pain started 
seven days before. He denied weight loss, nausea, 
vomiting, and digestive hemorrhage; and reported 
being a former smoker (five packs/year). There was no 
antecedent of Epstein-Barr virus infection, Wilms tumor, 
or immunosuppression. On physical examination, 
his BMI was 39.20 kg/m², with normal vital signs and 
unremarkable abdomen evaluation. The results of 
routine laboratory tests were normal. The computed 
tomography (CT) of the abdomen (Figure 1) showed a 
hypo vascular abdominal mass with cystic and necrotic 
degeneration, occupying the epigastrium and the left 
hypochondrium, with no cleavage plane with the 
border of the left hepatic lobe, and apparent continuity 
with the upper body wall of the excluded stomach 
(measuring 17.0 cm x 10.3 cm x 8.6 cm). The diagnostic 
suspicion was of primary neoplastic involvement, in 
addition to metastatic liver nodules. The CT of the chest 
showed a lytic lesion in the fourth left costal arch and 
solid nodules up to 1.0 cm distributed in both lungs, 
suggestive of metastases. Evaluation by upper digestive 
endoscopy revealed gastric bypass without changes. 
The colonoscopy procedure detected a rectal polypoid 
lesion and its resection yielded the diagnosis of 
leiomyoma. The tumor markers were within the normal 
range (carcinoembryonic antigen: 0.9, CA 125: 15.6, CA 
19-9: <2, and alpha-fetoprotein: 2.6). The biopsy of liver 
lesions revealed a poorly differentiated fusocellular 
neoplasia, with immunohistochemistry study indicating 
a high-grade mesenchymal malignancy with positive 
Ki-67 and vimentin. Three revisions of the slides did not 
demonstrate the immunoexpression of CD117. 
Figure 1: Abdominal CT scan (A and B, 2018) showing a hypovascular 
cystic-necrotic mass (arrows) in the excluded stomach (gastric 
pouch), and hepatic nodules; and (C and D, 2019) the persistence 
of both the hepatic nodules and the mass (arrows) with no apparent 
cleavage with the gastric pouch. 
Considering the strong hypothesis of a metastatic 
gastrointestinal stromal tumor (GIST) from the excluded 
stomach, the patient initially underwent a schedule 
with imatinib (400 mg/day) from July 2018 to June 
2019. Although the disease seemed stable with this 
therapy, the patient underwent another biopsy of the 
mass in the excluded stomach guided by ultrasound. 
The immunohistochemical panel showed vimentin 
V9 and actin 1A4 positive, while CD117 (c-kit), CD34, 
and S100 protein were negative. These data confirmed 
the diagnosis of leiomyosarcoma in an excluded 
stomach. Then, the chemotherapy changed by liposomal 
doxorubicin (75 mg/m²) from July till October 2019. 
Since December he is utilizing docetaxel in association 
with gemcitabine. The latest control imaging revealed 
the stability of the hepatic implants, bone lesions, and 
pulmonary nodules; however, the disease progressed 
affecting the central nervous system. Currently, the 
patient is clinically stable under follow-up care by the 
service of radiotherapy.
Discussion 
The male patient herein described underwent bariatric 
surgery for the management of his obesity. The RYGB 
procedure resulted in a reduction of his gastric volume 
by defining a small proximal gastric pouch without the 
remaining stomach [8]. This postoperative anatomy 
change corresponds to the called “excluded stomach” 
from the gastrointestinal tract. And the persistent 
alkaline effect of duodenal bile reflux has been related 
to the gastric cancer risk [8]. Excluded stomachs can 
harbor a great number of bacteria and fungi, with a 
variable degree of gastritis, atrophy, and intestinal 
metaplasia which may predispose to gastric malignancy 
[8]. An additional concern might be the finding of 
5-ciprinol sulphate, a toxic bile alcohol present in certain 
dysfunctional conditions, including inflammation 
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and hepatic carcinogenesis [8]. Notwithstanding, with 
respect specifically to gastrointestinal LMS, the known 
predisposing factors include a history of Wilms tumor, 
immunosuppression, and EBV infection [2]. Worthy 
of note in this setting is the underestimated diagnosis 
of malignancy in the excluded stomach because of the 
difficult endoscopic evaluation of this special anatomical 
region [8]. Concordant with literature, the patient was in 
the sixth decade of life, had an insidious clinical course 
with no-specific abdominal pain, and presented with liver 
metastasis at diagnosis. And his poor outcome included 
recent implants in bones, lungs, and the central nervous 
system. There was no remarkable response of distant 
metastases to the chemotherapy schedules [6]. Because 
of the development of brain implants, he was referred to 
treatment by radiotherapy. Although the results of this 
therapy are usually poor, that is also a resource utilized 
in LMS. The first hypothesis of GIST was ruled out by 
CD117 (c-kit) and CD34 negativity, while the positivity 
of vimentin V9 and actin 1A4 were consistent with the 
diagnosis of gastric LMS. Except for the previous RYGB, 
there was no significant risk factor for gastric malignancy 
[8]. Late diagnosis and misdiagnosis of gastrointestinal 
LMS with GISTS are frequent, as well as multiple 
metastases at diagnosis, unsatisfactory therapeutic 
responses, and poor outcomes. Cheng et al. reported a 
43-year-old woman with a previous resection by Billroth 
I procedure of a gastric tumor (3cm) 1 year ago [1]. 
Symptoms were weakness and abdominal discomfort. 
The initial diagnosis was a spindle cell tumor and she 
had no postoperative adjuvant therapy. Histological, 
immunohistochemical and genetic evaluations done 
by authors showed an LMS. The results were SMA 
(+), calponin (+), CD34 (-); CD117 (-), DOG (-), desmin 
(doubtful), S-100 (-), Ki-67 (15%+); and no KIT exon 
9, 11, 13, 17, or PDGFRA exon 12 or 18 mutation. The 
patient claimed of low back pain, had severe anemia, 
liver, and lymph node metastases. She underwent 
transarterial chemoembolization with oxaliplatin and 
tetrahydropalmatine emulsion with lipiodol, plus 
high-intensity focused ultrasound for retroperitoneal 
metastases. The choice of this alternative management 
was due to her fragile clinical general status [1]. 
Gubatan and Shah reported a 50-year-old man with 
the antecedent of Wilms tumor and presenting 
with gastrointestinal bleeding by a percutaneous 
endoscopic gastrostomy tube [2]. The endoscopy 
showed a large, ulcerated mass on the gastric body. The 
immunohistochemical study was consistent with LMS 
[positive for cytokeratin, calponin, actin, and desmin 
(focal); and negative for CD117, S100, CK5/6, Cam5.2, 
ALK-1, CD34, CD31, and myogenin]. The patient and 
his family decided against any kind of therapy because 
of his poor prognosis [2]. Hasnaoui et al. described 
the case of a 63-year-old woman, with longstanding 
anemia due to digestive bleeding and the endoscopy 
revealed an ulcerated tumor (9 cm) on the cardia 
[3]. The immunohistochemistry evaluation revealed 
positivity for vimentin, smooth muscle actin (SMA), and 
h-caldesmon, while the immunoreactivity for both KIT 
and DOG1 was doubtful. With no peritoneal or liver 
metastasis, she had total gastrectomy with uneventful 
course [3]. Kang et al. reported a 57-year-old woman with 
digestive bleeding of long duration caused by a gastric 
tumor without evidence of metastasis and was resected, 
with no adjuvant treatment. Immunohistochemical 
study showed SMA (+), desmin (+), CD117 (-), DOG1 (-), 
CD34 (-), S-100(-), and Ki-67 index (50%). For a definitive 
diagnosis, we performed targeted next-generation 
sequencing. The genes revealed in the panel included 
KIT, PDGFRA, SDHA, SDHB, SDHC, SDHD, BRAF, 
KRAS, NRAS, and EGFR, without mutations in any of 
them. The patient died with gastrointestinal obstruction 
and malnutrition one year after surgery [4]. 
Mehta et al. described a 47-year-old male two years after 
the diagnosis of a huge gastric LMS (130 mm x 130 mm 
x 100 mm) in the greater curvature, and then excised 
by laparotomy [6]. Immunohistochemistry studies of 
primary and liver metastatic lesions showed positivity 
for alpha-smooth muscle actin, and h-caldesmon, and 
negativity for CD117, DOG-1, and S100. Two years 
after receiving six cycles of doxorubicin, multiple liver 
metastases developed, and he underwent gemcitabine-
docetaxel chemotherapy without significant response. 
Further pazopanib administration resulted in a reduction 
(approximately 17%) of metastasis diameter. The authors 
commented that resection plus chemotherapy is the first 
option for liver metastases of LMS, but the presence of 
multiple lesions made the patient not suitable for hepatic 
resection [6].
Conclusion: 
The evolution of our patient corresponds to descriptions 
of other cases of this malignancy. The diagnosis of 
gastric LMS often occurs at late stages because of the 
insidious clinical course. The rate of liver metastasis at 
diagnosis is high. Besides, the relatively poor response 
to the alternative management for non-surgical stages 
of the disease yields severe outcomes. Close control of 
the excluded stomach is necessary after RYGB due to the 
risk of malignancy. 
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